Top Statins Have Equally Low Rhabdomyolysis Risk, Says Graham In JAMA
This article was originally published in The Tan Sheet
Executive Summary
The top three statins - Zocor, Lipitor, and Pravachol -have roughly equivalent low risks of rhabdomyolysis, according to a study of health plan prescription data released by the Journal of the American Medical Association Nov. 23
You may also be interested in...
Mevacor OTC Study Shows High-Risk Users Will “Upstream,” Merck Says
Merck's educational strategy for potential over-the counter sale of 20 mg Mevacor (lovastatin) will prevent rather than increase undertreatment among people who should be using more aggressive statin therapy, the firm contends
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands